Trials / Completed
CompletedNCT05712642
A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity
A Dosing Study of Two Different Doses (0.3125mg Versus 0.625mg) Intravitreal Bevacizumab for Type 1 ROP (Retinopathy of Prematurity)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- All
- Age
- 28 Weeks – 40 Weeks
- Healthy volunteers
- Not accepted
Summary
The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding : Serum Systemic VEGF levels. Retinal Vascularization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravitreal Bevacizumab | Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-12-30
- Completion
- 2021-01-28
- First posted
- 2023-02-03
- Last updated
- 2023-02-03
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05712642. Inclusion in this directory is not an endorsement.